Advancing the Future of Regenerative Medicine | Translating Breakthrough Science into Patient Care
"From Bench to Bedside: Innovating Regenerative Therapies for Global Health"
From technology commercialization to clinical-grade testing and world-class literature resources — all under one Harvard-endorsed platform.
Full-chain commercialization services for Harvard regenerative medicine research achievements, following U.S. Office of Technology Licensing (OTL) standards — connecting research, patent, industry, and market.
Compliant testing services meeting GLP, ISO 17025, and CLIA standards. Authoritative testing qualifications providing full-process support for biological products, cell therapies, and peptide products.
A world-top regenerative medicine literature search and analysis platform endorsed by Harvard, integrating 1M+ high-quality academic resources for researchers, clinicians, and enterprise R&D teams.
[ Auto-rotating : 3 scenes ]
The Harvard Regenerative Medicine Institute (HRMI) is a world-leading research institute affiliated with Harvard Medical School, dedicated to translating groundbreaking regenerative medicine discoveries into clinical solutions for patients worldwide. Our team of Harvard faculty, researchers, and industry experts bridges the gap between bench science and bedside care, driving innovation in cell therapy, gene editing, tissue engineering, and precision medicine.
"To Cure, To Heal, To Regenerate: Advancing Human Health Through Regenerative Medicine"
Full-process U.S. technology transfer standards — from preclinical development to regulatory approval and global market entry.
Full-process preclinical support complying with FDA IND application standards.
Full-process Phase I–IV clinical trial services, GCP-compliant, Harvard Clinical Center resources.
Full-life-cycle patent protection services, maximizing IP value, Harvard IP policy compliant.
Full-process consulting for global regenerative medicine regulatory compliance.
Relying on Harvard Clinical Center resources, providing full-process Phase I–IV clinical trial services complying with GCP standards.
Evaluating the efficacy and safety of recombinant hirudin in patients with acute coronary syndrome. Multi-center, randomized, double-blind trial.
Large-scale Phase III trial assessing nattokinase as a prophylactic agent in high-risk thrombosis populations. FDA IND approved.
First-in-human safety study of a novel peptide scaffold for articular cartilage regeneration. Results published in Nature Medicine.
Authoritative testing qualifications; legally binding test reports recognized internationally.
Strict GLP standards ensuring authenticity, reliability, and traceability of experimental data.
Clinical testing services with FDA-recognized results for diagnostic and research applications.
Potency testing for cell therapies, protein drugs, peptides, Hirudin, and Nattokinase.
Long-term, accelerated, and stress testing; impurity profiling for heavy metals and microorganisms.
Submit online application, fill in sample information and testing requirements, obtain submission number.
Laboratory receives, verifies, and registers samples into the management system for full traceability.
Standardized testing using professional instruments; data recorded for accuracy assurance.
Professional quality auditors review data and processes; audit opinions issued.
FDA/ISO-compliant test reports delivered via email; online download and query available.
Result interpretation, compliance suggestions, and re-testing services provided on request.
Access 1M+ peer-reviewed publications across all regenerative medicine subdivisions. Curated by Harvard Medical School faculty, updated daily.
Precise screening by author, journal, year, research direction, and literature type. Save search conditions for quick repeat queries.
Customize research directions and keywords. System pushes latest relevant literature daily, weekly, or monthly via email or in-site messages.
Bibliometric analysis, citation networks, and trend prediction. Generate literature citation networks and research hotspot trend charts.
In-depth interpretations of cutting-edge regenerative medicine research by Harvard Medical School professors and leading global experts.